Trial Profile
A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Interleukin-7 (Primary) ; Interleukin-7 (Primary)
- Indications Lymphopenia; Sepsis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms IRIS-7-B
- Sponsors Revimmune LLC
- 29 Aug 2018 Status changed from active, no longer recruiting to completed.
- 24 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
- 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.